Annual Report

Overview

The report presents Kuros's 2024 commercial acceleration, with Total Medical Device sales reaching CHF 75.6 million after 125% growth and the first positive EBITDA. It highlights landmark MagnetOs clinical evidence, including a 79% fusion rate versus 47% for autograft. The report also describes Kuros's international expansion and says its ESG framework is still in the early stages of formalization.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services